Integrative analyses identify modulators of response to neoadjuvant aromatase inhibitors in patients with early breast cancer
Elena López‐Knowles(Breast Cancer Now), Mitch Dowsett(Institute of Cancer Research), J. Michael Dixon(University of Colorado Denver), Ricardo Ribas(Institute of Cancer Research), Aradhana Rani(Institute of Cancer Research), A Nerurkar(Royal Marsden Hospital), Anita K. Dunbier(University of Otago), Zara Ghazoui(AstraZeneca (Sweden)), Lorna Renshaw(NHS Lothian), Alan Mackay(Institute of Cancer Research), Jorge S. Reis‐Filho(AstraZeneca (France)), Alexey A. Larionov(NHS Lothian), Lesley‐Ann Martin(Institute of Cancer Research), Peter Osin(Royal Marsden Hospital), H Anderson, Paul M Wilkerson(University Hospitals Bristol NHS Foundation Trust), William R. Miller(Houston Methodist)
Cited by 9
Related Papers
American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Immunohistochemical Testing of Estrogen and Progesterone Receptors in Breast Cancer
|Journal of Clinical Oncology|2010|4.3k
Patient-derived organoids model treatment response of metastatic gastrointestinal cancers
|Science|2018|2.1k
2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial
|The Lancet|2007|1.5k
Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features
|Proceedings of the National Academy of Sciences|2009|1.4k